BCL2 and ovarian carcinoma: Blocking the function of MAM-localized BCL2, which interacts with IP3R, via a BCL2 inhibitor disrupts Ca2+ translocation and leads to an increase in the cellular Ca2+ level in cisplatin-resistant ovarian cancer cells.